Dr. Kumar’s Take:
Every one of the 26 trials in this review tested ezetimibe added on top of other lipid-lowering drugs, mostly statins, against those drugs alone or plus placebo. So this evidence tells me what ezetimibe adds to a statin, not what it does by itself. On that question the answer is a modest one: fewer non-fatal heart attacks and non-fatal strokes, and no effect on dying, either from heart disease or from any cause. The benefit came mainly from people who already had established atherosclerotic cardiovascular disease, predominantly acute coronary syndrome. If you are doing well on a statin and you are not in that high-risk group, I do not see a strong case for adding ezetimibe. If your LDL stays high on maximal statin therapy after a cardiac event, it is a reasonable add-on, with modest expectations.
Key Takeaways:
✔ All 26 trials tested ezetimibe added to other lipid-lowering drugs, not ezetimibe on its own.
✔ Ezetimibe plus a statin probably lowers the risk of non-fatal heart attack and non-fatal stroke.
✔ It has little or no effect on death from heart disease or death from any cause.
✔ The review’s authors concluded that evidence on ezetimibe monotherapy and on primary prevention is limited and needs further study.
Brief Summary:
This 2018 Cochrane systematic review pooled 26 randomised controlled trials involving 23,499 participants, with evidence current to July 2018. Every included trial compared ezetimibe plus other lipid-modifying drugs against those drugs alone or plus placebo. Adding ezetimibe probably reduced major adverse cardiovascular events, non-fatal heart attacks and non-fatal strokes. It had little or no effect on cardiovascular death or all-cause death. The authors rated the effect as modest and noted that the beneficial findings came mainly from people with established atherosclerotic cardiovascular disease taking ezetimibe plus a statin.
Study Design:
This was a systematic review and meta-analysis of 26 randomised controlled trials. All 26 compared ezetimibe plus other lipid-modifying drugs against those same drugs alone or plus placebo, so no trial in the review tested ezetimibe as a standalone therapy. Participants were adults, with or without cardiovascular disease, and follow-up was at least 12 months. The findings were driven by the largest trial, IMPROVE-IT, which carried weights ranging from 41.5% to 98.4% across the different meta-analyses. Two authors independently selected studies, extracted data and assessed risk of bias, and the evidence was graded with GRADE.
Results:
✔ Major adverse cardiovascular events fell from 284 per 1,000 to 267 per 1,000 (95% CI 256 to 278) with ezetimibe added to statins, risk ratio 0.94 (95% CI 0.90 to 0.98), 21,727 participants, 10 studies, moderate-quality evidence.
✔ Non-fatal heart attacks fell from 105 per 1,000 to 92 per 1,000 (95% CI 85 to 100), risk ratio 0.88 (95% CI 0.81 to 0.95), 21,145 participants, 6 studies, moderate-quality evidence.
✔ Non-fatal strokes fell from 32 per 1,000 to 27 per 1,000 (95% CI 23 to 31), risk ratio 0.83 (95% CI 0.71 to 0.97), 21,205 participants, 6 studies, moderate-quality evidence.
✔ All-cause death was unchanged, risk ratio 0.98 (95% CI 0.91 to 1.05), 21,222 participants, 8 studies, high-quality evidence, and cardiovascular death was unchanged, risk ratio 1.00 (95% CI 0.89 to 1.12), 19,457 participants, 6 studies.
✔ Coronary revascularisation may have been reduced, from 196 per 1,000 to 184 per 1,000, risk ratio 0.94 (95% CI 0.89 to 0.99), though that difference disappeared when the analysis was limited to studies at low risk of bias.
✔ On safety, adding ezetimibe to statins may make little or no difference to liver injury, risk ratio 1.14 (95% CI 0.96 to 1.35), low-quality evidence, while the effect on myopathy remains uncertain, risk ratio 1.31 (95% CI 0.72 to 2.38), very low-quality evidence. Cancer, gallbladder-related disease and discontinuation due to adverse events showed little or no difference between groups.
✔ Lipids moved as expected: adding ezetimibe further lowered LDL cholesterol, total cholesterol and triglycerides and likely raised HDL cholesterol, though substantial heterogeneity appeared in most of these analyses.
How Ezetimibe Works for Cholesterol
Ezetimibe is a selective cholesterol absorption inhibitor. It blocks cholesterol uptake in the intestine and lowers LDL cholesterol, which is why it is used as an add-on when a statin alone does not get a patient to goal. The review’s authors suggest the cardiovascular benefit of ezetimibe may run through that reduction in LDL cholesterol, total cholesterol and triglycerides. Even so, lipid numbers are a means, not the endpoint, and the outcome data here are what tell you how much the drug actually buys.
Related Studies and Research
Red Yeast Rice and Metabolic Syndrome: Investigates how red yeast rice affects lipid levels and metabolic markers in people with metabolic syndrome.
Plant Sterols, Cholesterol, and Heart Health: Reviews how plant sterols impact cholesterol levels and their potential role in heart disease prevention.
Fibrates and Cardiovascular Risk Reduction: Explores the role of fibrates in lipid management and their effect on heart disease risk.
CETP Inhibitors and Cardiovascular Outcomes: Reviews studies on CETP inhibitors and their effect on HDL levels and cardiovascular risk.
PCSK9 and Ezetimibe: Heart Risk Reduction: Investigates how ezetimibe performs when used alongside PCSK9 inhibitors to lower risk.
Statins and Heart Disease: A Review: Examines the role of statins in managing heart disease, comparing efficacy with non-statin therapies.
Frequently Asked Questions
Does this review show ezetimibe works on its own?
It cannot answer that. All 26 trials gave ezetimibe on top of other lipid-lowering drugs, and the authors concluded that evidence on ezetimibe monotherapy, and on its role in primary prevention, is limited and requires further investigation.
Is ezetimibe safe?
Added to a statin, it may make little or no difference to liver injury, and cancer, gallbladder disease and treatment discontinuation were similar between groups. The authors rated this safety evidence low to very low quality, so it is not strong enough to settle the question either way.
Should I ask my doctor about ezetimibe?
If you have established cardiovascular disease and are not reaching your cholesterol goal on a statin alone, adding ezetimibe gives a modest reduction in non-fatal heart attack and stroke. That is the population where the benefit was demonstrated.
Does it reduce my risk of dying?
No. Trials reporting all-cause mortality found little or no effect, and that finding was graded high-quality evidence. Cardiovascular death was also unchanged.
Conclusion
Moderate to high-quality evidence says ezetimibe added to a statin has a modest beneficial effect on cardiovascular endpoints, driven by fewer non-fatal heart attacks and fewer non-fatal strokes, with little or no effect on fatal endpoints. That benefit was shown in people with established atherosclerotic cardiovascular disease, predominantly after acute coronary syndrome, taking ezetimibe alongside a statin. My read: it is a sensible incremental add-on in the right patient, and nothing in this review supports using it as a substitute for the therapies it was tested on top of.
